167 related articles for article (PubMed ID: 30500301)
1. Nanomedicine for cutaneous tumors - lessons since the successful treatment of the Kaposi sarcoma.
F Longo JP; Lucci CM; Muehlmann LA; Azevedo RB
Nanomedicine (Lond); 2018 Dec; 13(23):2957-2959. PubMed ID: 30500301
[No Abstract] [Full Text] [Related]
2. Progress and challenges towards targeted delivery of cancer therapeutics.
Rosenblum D; Joshi N; Tao W; Karp JM; Peer D
Nat Commun; 2018 Apr; 9(1):1410. PubMed ID: 29650952
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin.
Boehringer M; Schwarz A; Keller F
Nephrol Dial Transplant; 1999 May; 14(5):1342-3. PubMed ID: 10344407
[No Abstract] [Full Text] [Related]
4. Retinoids promising in Kaposi's sarcoma trials.
Ault A
Lancet; 1998 Apr; 351(9110):1185. PubMed ID: 9643704
[No Abstract] [Full Text] [Related]
5. Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
Fournier S; Dupont B; Pialoux G; Eliaszewicz M; Gonzalez-Canali G; Feuillie V
Arch Dermatol; 1997 Jul; 133(7):918-9. PubMed ID: 9236538
[No Abstract] [Full Text] [Related]
6. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.
James ND; Coker RJ; Tomlinson D; Harris JR; Gompels M; Pinching AJ; Stewart JS
Clin Oncol (R Coll Radiol); 1994; 6(5):294-6. PubMed ID: 7530036
[TBL] [Abstract][Full Text] [Related]
7. Liposomal KS drugs approved.
GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide in Kaposi sarcoma: promising or disappointing?
Laffitte E
Dermatology; 2007; 215(3):171-2. PubMed ID: 17823510
[No Abstract] [Full Text] [Related]
9. Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives.
Akasbi Y; Awada A; Arifi S; Mellas N; El Mesbahi O
Bull Cancer; 2012 Oct; 99(10):92-9. PubMed ID: 23017657
[TBL] [Abstract][Full Text] [Related]
10. [Clinical remission of classic Kaposi sarcoma with topical 5% imiquimod].
Echeverría-García B; Sanmartín O; Guillén C
Actas Dermosifiliogr; 2010 Mar; 101(2):181-2. PubMed ID: 20223165
[No Abstract] [Full Text] [Related]
11. Alitretinoin (Panretin) gel 0.1%.
Rhoads J
J Assoc Nurses AIDS Care; 2001; 12(5):86-91. PubMed ID: 11565242
[TBL] [Abstract][Full Text] [Related]
12. Doxil receives FDA market clearance.
AIDS Patient Care STDS; 1996 Apr; 10(2):135. PubMed ID: 11361702
[No Abstract] [Full Text] [Related]
13. Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases.
Meseguer-Yebra C; Cardeñoso-Álvarez ME; Bordel-Gómez MT; Fraile-Alonso MC; Pérez-Losada ME; Sánchez-Estella J
Br J Dermatol; 2015 Sep; 173(3):860-2. PubMed ID: 25704866
[No Abstract] [Full Text] [Related]
14. Imiquimod for the treatment of classical Kaposi's sarcoma.
Bernardini B; Faggion D; Calabró L; Oro E; Alaibac M
Acta Derm Venereol; 2010 Jul; 90(4):417-8. PubMed ID: 20574613
[No Abstract] [Full Text] [Related]
15. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience.
Rongioletti F; Zaccaria E; Viglizzo G
Br J Dermatol; 2006 Oct; 155(4):856-7. PubMed ID: 16965450
[No Abstract] [Full Text] [Related]
16. [Cytostatic agents in dermatology].
Luger A
Z Hautkr; 1978 Dec; 53(23):857-70. PubMed ID: 726543
[No Abstract] [Full Text] [Related]
17. Lipid-based drug delivery systems for cancer treatment.
Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of iatrogenic Kaposi's sarcoma with low-dose docetaxel therapy.
Yamashiro A; Awazawa R; Ohira A; Hirata T; Zamami R; Miyagi T; Takahashi K
J Dermatol; 2018 Apr; 45(4):e96-e97. PubMed ID: 29215145
[No Abstract] [Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in nanomedicine and survivin targeting in brain cancers.
Mazur J; Roy K; Kanwar JR
Nanomedicine (Lond); 2018 Jan; 13(1):105-137. PubMed ID: 29161215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
